MGMT and glioblastoma: Aside from the MGMT promoter methylation status for guiding temozolomide-based treatments, actionable driver mutations and immune checkpoint status have emerged as candidate biomarkers to inform targeted therapy and immunotherapy, respectively, for managing GBM {Tan, 2020 #319}.